Menu Search
Equities

Adimmune Corp

4142:TAI

Adimmune Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)22.35
  • Today's Change0.150 / 0.68%
  • Shares traded1.14m
  • 1 Year change-32.48%
  • Beta--
Data delayed at least 20 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TWDIncome statement in TWDView more

Year on year Adimmune Corp's revenues fell -20.72% from 2.25bn to 1.79bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 290.98m to a loss of 639.89m.
Gross margin27.82%
Net profit margin-44.75%
Operating margin-40.57%
Return on assets-8.27%
Return on equity-11.38%
Return on investment-10.19%
More ▼

Cash flow in TWDView more

In 2023, cash reserves at Adimmune Corp fell by 399.58m. Cash Flow from Financing totalled 859.30m or 48.14% of revenues. In addition the company used 892.35m for operations while cash used for investing totalled 366.56m.
Cash flow per share-1.24
Price/Cash flow per share--
Book value per share11.92
Tangible book value per share11.78
More ▼

Balance sheet in TWDView more

Adimmune Corp has a Debt to Total Capital ratio of 32.84%, a lower figure than the previous year's 35.50%.
Current ratio2.64
Quick ratio1.99
Total debt/total equity0.5245
Total debt/total capital0.3284
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.